This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Today's Health Winners and Losers

Shares of Valeant Pharmaceuticals (VRX) were among the worst-performing health-related stocks Tuesday, slumping 15% after the drugmaker's phase III trial of a hepatitis C treatment failed to meet one of its key goals.

While the company's Viramidine drug fared well in overall safety compared to ribavirin, the study showed that it didn't meet an efficacy endpoint. The company said that the sustained viral response rate for Viramidine was 38% compared to 52% for ribavirin. "However," the company said, "the SVR rates were adversely impacted by the effect of lower dosing on a mg/kg basis in the Viramidine arm and by statistically inconsistent results seen in the rest of the world region." The company said it continues to work toward a commercial launch of the treatment, which is expected before the end of 2007. Shares were trading down $2.79 to $15.89.

Novavax (NVAX) fell 8% after the company said it plans to sell 5.2 million shares of stock for $7.30 apiece, raising some $38 million. The sale price represents a 12% discount to Monday's closing price of $8.31. Novavax plans to use proceeds from the offering to fund general corporate needs. Rodman & Renshaw acted as the placement agent for the offering. Shares were trading down 64 cents to $7.67.

Shares of NitroMed (NTMD) rose 7% after the company announced the departure of its chief executive, Michael Loberg, and chief financial officer, Lawrence Bloch. The resignations are effective immediately. The drug company didn't offer an explanation for the departures, but the resignations come less than three weeks after NitroMed posted disappointing fourth-quarter results. Argeris Karabelas, the company's chairman, will assume the CEO position on an interim basis. Kenneth Bate, meanwhile, will become CFO as well as chief operating officer. Shares were trading up 54 cents to $8.37.

Biomet (BMET) fell 4% after the medical device company posted weaker-than-expected third-quarter revenue and offered tepid guidance. The company earned $106.1 million, or 43 cents a share, on revenue of $506.3 million. Analysts polled by Thomson First Call expected earnings of 43 cents a share and revenue of $516.3 million. During the year-earlier period, the company earned $96.8 million, or 38 cents a share, on revenue of $482 million. On an adjusted basis, the company earned $101.6 million, or 40 cents a share, a year earlier.

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 18,053.71 +23.50 0.13%
S&P 500 2,088.77 +6.89 0.33%
NASDAQ 4,806.8590 +33.3870 0.70%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs